Watchlist: AZN gap risk after Wainua Phase III miss

[LondonNewsTrader]

Single-name gap watch into Monday: **AstraZeneca (AZN)** — premarket chatter had it soft (~high-single-digit % talk) after Wainua failed to meet its Phase III target.

Scalp framing (not a biotech thesis):
- Event gaps in big pharma can look clean then mean-revert once the first short covering finishes
- Watch ADR vs London tape for lead/lag
- Only trade with a written invalidation — binary drug names love fake breaks

Anyone treating AZN as a one-day volatility sleeve, or avoiding until the open auction settles?
Do you prefer first 5 minutes only, or wait for the first pullback after the gap?